A clinical study to see the effect of Ayurvedic preparations on Shushkakshipaka

A Randomized Open Label Clinical Trial To Evaluate The Efficacy OF SHADANGA GUGGULU Orally And KESHANJANA Local Application In The Management Of SHUSHKAKSHIPAKA With Special Reference To Meibomian Gland Dysfunction Â

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/034913

Enrollment

Registered

2021-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H028- Other specified disorders of eyelid

Interventions

Intervention1: Group A: 15 patients of MGD (Shushkakshipaka) will be given Shadanga Guggulu orally and Keshanjana topically for 15 days Control Intervention1: Group B: 15 patients of MGD (Shushkakship

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18 years and older patients of either sex. 2. Patients presenting with signs and symptoms of Shushkakshipaka. 3. Patients presenting with signs of MGD â?? a. Ocular dryness. b. Lid margin thickening or irregularity. c. Meibomian gland orifice plugging. d. Cloudy, yellow or frothy meibomian gland secretions. e. Lid margin telangiectasia. f. Meibomian gland capping. 4. TBUT >5 seconds. 5. Schirmerâ??test >10mm

Exclusion criteria

Exclusion criteria: cases complicated with acute, chronic, infective conjunctivitis, any specific eyelid disorders, corneal ulcer, dacryocystitis and lagophthalmos 2. inflammatory diseases unrelated to M.G.D 3. Patient suffering from any systemic disorder or taking any medication which in the opinion of P.I. may affect the outcome of clinical trial 4. contact lenes users 5. history of ocular surgery within 6 months prior to enrollment in trial 6. patient suffering from Steven Jhonson Syndrome and Sjogren Syndrome

Design outcomes

Primary

Measure	Time frame
Changes in Meibomian Gland Dysfunction indexTimepoint: 3 weeks	—

Secondary

Measure	Time frame
Changes in OSDI score / Schein scoreTimepoint: 3 weeks	—

Countries

India

Contacts

Public ContactDr Anita Vishnoi

National Institute of Ayurveda Jaipur

shalakya007@gmail.com9461065960

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026